Archive | September, 2015

Hot Life Science Investor Mandate 1:Corporate Venture Capital Fund Seeking Therapeutics Investments

24 Sep

A corporate venture capital fund of a large pharmaceutical company is currently investing from its second fund of $100M. The firm invests in early-stage biotechnology companies focusing on discovering and developing human therapeutics primarily in the areas of the current therapeutic interest to its parent company. The firm typically invests (equity) $3-$4M per round with $10M reserved for follow-on investments. The firm seeks companies that are based in the US and Europe. The firm seeks to make about 2-3 allocations in the next 6-9 months.

The firm seeks early-stage companies developing human therapeutics. The firm is seeking companies with products in pre-clinical to phase II. The firm’s therapeutic areas of focus are: Cardiovascular (Acute Coronary Syndromes, Dyslipidemia, Heart Failure); Hematology (Anemia, Neutropenia, Stem Cell Mobilization); Inflammation (Asthma, Bowel Disease, Multiple Sclerosis, Osteoarthritis, Psoriasis, Rheumatoid arthritis, Systemic Lupus Erythematosus); Metabolic Disorders (Diabetes, Osteoporosis); Nephrology (Hyperparathyroidism, Renal Failure); Neuroscience (Alzheimer’s Disease, Cognition, Pain-Neuropathic & Inflammatory, Parkinson’s Disease, Schizophrenia); and Oncology. The firm is also interested in drug delivery therapeutics and Healthcare IT.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 2:Hong Kong Based VC Seeking US Based Life Science Investments

24 Sep

A venture capital founded in and based in Hong Kong, Shanghai, Beijing, and Suzhou, China has invested in nearly 50 healthcare companies in China and the U.S. across all sectors of life sciences from pharmaceuticals and medical devices to healthcare IT and diagnostics. The firm typically leads investments, though is also open to co-investing. The firm typically makes equity investments ranging from $1-$35 million, and currently has $1.7 billion in total assets under management, with their latest fund raised in 2014 at $500 million. The firm seeks to make 20-30 new investments within the next year, with a geographical focus in China. The firm is open to opportunities in the US, as the firm recently closed deals in Boston, San Francisco, and Los Angeles.

The firm is open to all sectors and subsectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm mostly invests in 510K devices due to its faster turnaround, but will also invest in devices in the PMA pathway depending on its stage. In therapeutics, the firm is interested in all subsectors including small molecule, biologics, cell therapy, and biosimilars. The firm invests in therapeutics that are past the pre-clinical stage at Phase I to on the market, as well as medical devices that are either at the clinical stage or on the market. The firm is also interested in lab equipment and drug development enabling technologies, and is open to all indications.

The firm prefers a company with a strong management team with experience in the space. The firm will help the company fill spaces in the team if necessary, and will typically take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 3:VC Fund Seeking Life Science Companies With Advanced Material Technologies

24 Sep

A VC fund based in the United States The firm invests in advanced materials technologies across several sectors, including life sciences. The firm is generally a lead investor, and commits up to $8 million per opportunity; investments may be tranched, with an initial commitment of $2-3 million. The firm is open to opportunities globally and has a partner based in Japan, but the firm primarily invests in North America.

The firm is interested in life science companies developing advanced material technologies. In the medtech sector, the firm is oriented toward diagnostic and delivery technologies (including both in vivo and ex vivo delivery); the firm is also interested in advanced materials technologies used in biotech R&D. Areas of interest include biomaterials, drug discovery tools, purification and separation techniques, electrochemistry, nanotechnology, microfluidics, and optics. In diagnostics, the firm is interested in new diagnostic applications of materials science including in sample collection, rapid tests, and biosensors used for real time monitoring; microbiomic diagnostics are also of interest. In addition to the aforementioned areas, the firm is interested in ‘blue sky’ applications of materials science in the life sciences.

The firm does not invest in products that are regulated as therapeutics; in the device space the firm is open to investing in 510k devices, but not PMA devices. However, the firm prefers to invest in technologies that do not require FDA approval. The firm invests in companies that have strong proof of concept data supporting their advanced materials. The firm is open to investing in companies that do not yet have products on the market.

The firm favors companies with partner-based business models, eg. companies developing an enabling technology that a larger partner will deploy to develop a new product. The firm has deep expertise in manufacturing; additionally, LPs include large pharma and medical device manufacturing companies, and the firm helps portfolio companies develop relationships with these strategics.If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: